Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative

• Published in: Journal of controlled release 2022-11, Vol.351, p.573-580
• Main Authors: Akita, Tomomi, Oda, Yusuke, Kimura, Ryosuke, Nagai, Mio, Tezuka, Ayano, Shimamura, Mizuki, Washizu, Kaho, Oka, Jun-Ichiro, Yamashita, Chikamasa
• Format: Article
• Language: English
• Subjects: Cell-penetrating peptide; Glucagon-like peptide-2; Nose to brain; Penetration accelerating sequence; Trigeminal nerve
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2022.09.047

In our previous study, we created a glucagon-like peptide-2 (GLP-2) derivative with the functional sequence PAS-CPP to achieve efficient uptake by the respiratory epithelium and trigeminal nerve. By using octaarginine for cell penetrating peptides (CPP) and FFLIPKG, a reverse sequence of a part of the cathepsin D sequence for the penetration accelerating sequence (PAS), we found that the derivative was taken up by the cells through macropinocytosis and efficiently escaped from the endosomes and exited the cells. Moreover, it showed drug effects by intranasal (in.) administration at the same dose as intracerebroventricular (icv.) administration, which is direct drug administration into the brain. The purpose of this study was to elucidate the cause of the drug effect of in. administered PAS-CPP-GLP-2 at the same dose as that by icv. administration. The present results suggested that although icv. administered PAS-CPP-GLP-2 entered the cerebrospinal fluid, it barely penetrated the perivascular space of the brain, and therefore, only a small amount of the administered dose may have reached the site of action in the brain. In contrast, it was qualitatively suggested that in. administered PAS-CPP-GLP-2 migrates from the trigeminal nerve to the central nervous system via the principal sensory trigeminal nucleus and then through the trigeminal lemniscus. The present results show that nose-to-brain delivery by trigeminal axons, which is assumed to be a transcellular pathway, may be possible. As the drug can be delivered into the nerve, it is expected to be applied not only as a central delivery route but also for the treatment of neurological diseases. [Display omitted] •Migration route of PAS-CPP-GLP-2 to brain differed in icv. vs. in. administration.•Intracerebroventricularly administered PAS-CPP-GLP-2 entered CSF and perivascular space.•Intranasally administered PAS-CPP-GLP-2 localized in the axon of the trigeminal nerve.